BTG Reports Positive Results From First Study Investigating BGC20-0166 In Obstructive Sleep Apnoea Patients

BTG (LSE: BGC), the life sciences company, reports additional details from its positive clinical proof of concept study of BGC20-0166 in subjects with mild to severe obstructive sleep apnea. BGC20-0166 is a novel combination of two marketed serotonin modulating drugs being developed for the treatment of obstructive sleep apnea syndrome (OSA).

More: continued here

Filed under: Sleep / Sleep Disorders on April 11th, 2008